undamentalytics Newsletter
Sign in

Amphastar Pharmaceuticals, Inc. cash flow statement

In fiscal 2025, Amphastar Pharmaceuticals, Inc.'s operations generated $156m of cash; it spent $34.9m on capital projects, leaving free cash flow of $121m. It returned $75.6m through buybacks.

Cash flow statement

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year2012Dec 20122013Dec 20132014Dec 20142015Dec 20152016Dec 20162017Dec 20172018Dec 20182019Dec 20192020Dec 20202021Dec 20212022Dec 20222023Dec 20232024Dec 20242025Dec 2025LTMJun 2026
Cash from operations−231211139393842579889184213156185
Depreciation and amortisation10111311126679101326283226
Stock-based pay769131517171720191820242729
Capital spending231820162135474234272438413532
Free cash flow−25131−5174−90237165145172121153
Free cash flow after stock pay−317−9−182−13−25−173524712514894124
Share buybacks1001010312522242940588576100
Shares issued——38————————————

Free cash flow is cash from operations minus capital spending. Free cash flow after stock pay also subtracts stock-based compensation, a real cost to shareholders that the cash flow statement adds back. Dividends, buybacks and shares issued are cash amounts for the period.

Compare with peers

Head to head: AMPH vs PCRXAMPH vs TVTXAMPH vs EBS

More: Pharmaceuticals stocks compared, Health Care sector, rankings of US companies

Figures from Amphastar Pharmaceuticals, Inc.'s SEC filings (10-K and 10-Q), retrieved October 29, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Amphastar Pharmaceuticals, Inc.